Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 28,000 shares at $134.09 ($3.7M) on 2024-06-18, disclosed to the SEC on 2024-06-21.
Scheduled sale ($3.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $132.22 | 1,700 | $225K | 6.0% |
| 2 | $133.26 | 6,160 | $821K | 21.9% |
| 3 | $133.26 | 6,160 | $821K | 21.9% |
| 4 | $134.09 | 6,840 | $917K | 24.5% |
| 5 | $134.09 | 6,840 | $917K | 24.5% |
| 6 | $135.02 | 200 |
| $27K |
| 0.7% |
| 7 | $136.92 | 100 | $14K | 0.4% |
| Total | $133.63 avg | 28,000 | $3.7M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |